ARTICLE | Company News
Ipsen, Teijin sales and marketing update
January 21, 2013 8:00 AM UTC
Teijin launched Somatuline lanreotide acetate in Japan to treat acromegaly and pituitary gigantism when surgery is not an option or response to surgery is not satisfactory. The national list price of is ¥180,360 ($2,020.03) for 60 mg, ¥253,900 ($2,843.68) for 90 mg and ¥323,624 ($3,624.59) for 120 mg subcutaneous Somatuline. The companies said the product can be given once every four weeks. Teijin and Ipsen have a joint development and marketing arrangement for the product in Japan. ...